Bluebird Bio Stock Strong Uptrend On Buy Ratings

While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.

Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.

BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio's latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio's precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.

Author: Lance Jepsen

For ethical purposes, I try not to hold any position in any stock I profile on unless specifically stated in the article. Owner of Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.

Leave a Reply